What is the Origin of GLP-1/GIP Co-Agonist?

The term is derived from the names of the two endogenous incretin hormones, GLP-1 and GIP, combined with "co-agonist," which signifies a substance that activates two distinct receptor types concurrently. This pharmacological nomenclature precisely describes the drug's dual mechanism of action.

What is the Mechanism of GLP-1/GIP Co-Agonist?

The drug acts as a molecular key, binding to and activating both the GLP-1 receptor and the GIP receptor on target cells. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. GIP receptor activation further enhances insulin secretion and may also promote beta-cell survival and improve lipid metabolism. The combined signaling pathways result in a potent, complementary effect on energy balance and glucose regulation.

GLP-1/GIP Co-Agonist ∞ Area

GLP-1/GIP Co-Agonist

Meaning

A GLP-1/GIP Co-Agonist is a novel class of pharmaceutical agent designed to simultaneously activate the receptors for two key incretin hormones: Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). This dual agonism provides a synergistic therapeutic effect, resulting in superior glucose control and greater weight loss compared to single-agonist treatments. These agents represent a significant advancement in the management of type 2 diabetes and obesity.